Dual Targeting of Smoothened, a Key Regulator in the Hedgehog Pathway, and BCR-ABL1 Effectively Eradicates Drug-Insensitive Stem/Progenitor Cells in Chronic Myeloid Leukemia.

Kelly A Turner, Min Chen, Katharina Rothe, Donna L Forrest, Xiaoyan Jiang

Abstract read

In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Drug resistance in chronic myeloid leukemia: the involvement of Galectin-1 and Galectin-3.Molecular biology reports · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kelly A TurnerCollings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V6T 1Z3, Canada.

Min ChenCollings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V6T 1Z3, Canada.

Katharina RotheCollings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V6T 1Z3, Canada.

Donna L ForrestLeukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, BC V6T 1Z3, Canada.

Xiaoyan JiangCollings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V6T 1Z3, Canada.ORCID 0000-0002-8974-7340

Funding

CIHR 427201

6 · The paper itself

Abstract

Overcoming drug resistance and targeting cancer stem cells remain challenges for curative cancer treatment. In particular, patients with chronic myeloid leukemia (CML) often require lifelong therapy with ABL1 tyrosine kinase inhibitors (TKIs), partly due to a persistent population of TKI-resistant leukemic stem cells (LSCs). Therefore, identifying specific pathways crucial for LSC maintenance is necessary. The Hedgehog (HH) pathway, especially the protein Smoothened (SMO), has been found to be essential for CML LSCs, but its role in TKI resistance is still largely unknown. We have now demonstrated that the expression of HH pathway genes

Indexed as

Drug Resistance, NeoplasmFusion Proteins, bcr-ablHedgehog ProteinsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNeoplastic Stem CellsSmoothened ReceptorAnimalsCell Line, TumorHumansMiceNuclear ProteinsProtein Kinase InhibitorsSignal TransductionZinc Finger Protein Gli2Fusion Proteins, bcr-ablGLI2 protein, humanHedgehog ProteinsNuclear ProteinsProtein Kinase InhibitorsSmoothened ReceptorSMO protein, humanZinc Finger Protein Gli2Bostutinibchronic myeloid leukemiaGlasdegib (PF-04449913)Hedgehog pathwayleukemic stem cellsSmoothenedtherapy-resistancetyrosine kinase inhibitors

Identifiers

PMID41090792

DOI10.3390/cells14191565

PMCPMC12523657

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.